Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers

Journal of Clinical Oncology

Volumn 24, Issue 31, 2006, Pages 5043-5051

  Griffith, Obi L ^a   Melck, Adrienne ^a   Jones, Steven J M ^a   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC TEST; GENE EXPRESSION; GENE MAPPING; HUMAN; META ANALYSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THYROID CANCER; THYROID TUMOR; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; REPRODUCIBILITY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REPRODUCIBILITY OF RESULTS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750943691     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.7330     Document Type: Article

References (62)

1. Gharib H, Goellner JR: Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med 118:282-289, 1993
2. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
3. Goellner JR, Gharib H, Grant CS, et al: Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 31:587-590, 1987
4. Caraway NP, Sneige N, Samaan NA: Diagnostic pitfalls in thyroid fine-needle aspiration: A review of 394 cases. Diagn Cytopathol 9:345-350, 1993
5. Ravetto C, Colombo L, Dottorini ME: Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: A retrospective study in 37,895 patients. Cancer 90:357-363, 2000
6. Wiseman SM, Baliski C, Irvine R, et al: Hemithyroidectomy: The optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm. Ann Surg Oncol 13:425-432, 2006
7. Schena M, Shalon D, Davis RW, et al: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470, 1995
8. Lockhart DJ, Dong H, Byrne MC, et al: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14:1675-1680, 1996
9. Velculescu VE, Zhang L, Vogelstein B, et al: Serial analysis of gene expression. Science 270:484-487, 1995
10. Rhodes DR, Yu J, Shanker K, et al: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 101:9309-9314, 2004
11. Cahan P, Ahmad AM, Burke H, et al: List of lists-annotated (LOLA): A database for annotation and comparison of published microarray gene lists. Gene 360:78-82, 2005
12. Shih W, Chetty R, Tsao MS: Expression profiling by microarrays in colorectal cancer. Oncol Rep 13:517-524, 2005
13. Griffith OL, Pleasance ED, Fulton DL, et al: Assessment and integration of publicly available SAGE, cDNA microarray, and oligonucleotide microarray expression data for global coexpression analyses. Genomics 86:476-488, 2005
14. Lee HK, Hsu AK, Sajdak J, et al: Coexpression analysis of human genes across many microarray data sets. Genome Res 14:1085-1094, 2004
15. Pruitt KD, Katz KS, Sicotte H, et al: Introducing RefSeq and LocusLink: Curated human genome resources at the NCBI. Trends Genet 16:44-47, 2000
16. Mammalian Gene Collection Program Team, Strausberg RL, Feingold EA, et al: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A 99:16899-16903, 2002
17. Dennis G Jr, Sherman BT, Hosack DA, et al: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3, 2003
18. Arnaldi LA, Borra RC, Maciel RM, et al: Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15:210-221, 2005
19. Chevillard S, Ugolin N, Vielh P, et al: Gene expression profiling of differentiated thyroid neoplasms: Diagnostic and clinical implications. Clin Cancer Res 10:6586-6597, 2004
20. Onda M, Emi M, Yoshida A, et al: Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer 11:843-854, 2004
21. Yano Y, Uematsu N, Yashiro T, et al: Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10: 2035-2043, 2004
22. Strausberg RL, Buetow KH, Greenhut SF, et al: The cancer genome anatomy project: Online resources to reveal the molecular signatures of cancer. Cancer Invest 20:1038-1050, 2002
23. Huang Y, Prasad M, Lemon WJ, et al: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98:15044-15049, 2001
24. Belfiore A, Gangemi P, Costantino A, et al: Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 82:2322-2328, 1997
25. Ippolito A, Vella V, La Rosa GL, et al: Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Thyroid 11:783-787, 2001
26. Ramirez R, Hsu D, Patel A, et al: Overexpression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 53:635-644, 2000
27. Inaba M, Sato H, Abe Y, et al: Expression and significance of c-met protein in papillary thyroid carcinoma. Tokai J Exp Clin Med 27:43-49, 2002
28. Di Renzo MF, Olivero M, Ferro S, et al: Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7:2549-2553, 1992
29. Finley DJ, Arora N, Zhu B, et al: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89: 3214-3223, 2004
30. Hamada A, Mankovskaya S, Saenko V, et al: Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas. Cancer Lett 224:289-301, 2005
31. Hawthorn L, Stein L, Varma R, et al: TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck 26:1069-1083, 2004
32. Takano T, Miyauchi A, Yoshida H, et al: High-throughput differential screening of mRNAs by serial analysis of gene expression: Decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas. Br J Cancer 90:1600-1605, 2004
33. Takano T, Miyauchi A, Yoshida H, et al: Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma. Cancer Lett 219: 91-96, 2005
34. Poblete MT, Nualart F, del Pozo M, et al: Alpha 1-antitrypsin expression in human thyroid papillary carcinoma. Am J Surg Pathol 20:956-963, 1996
35. Wasenius VM, Hemmer S, Kettunen E, et al: Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: A cDNA and tissue microarray study. Clin Cancer Res 9:68-75, 2003
36. Maeta H, Ohgi S, Terada T: Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438:121-128, 2001
37. Hesse E, Musholt PB, Potter E, et al: Oncofoetal fibronectin-a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma. Br J Cancer 93:565-570, 2005
38. Liu W, Asa SL, Ezzat S: 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 19:2349-2357, 2005
39. Prasad ML, Pellegata NS, Huang Y, et al: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48-57, 2005
40. Lazar V, Bidart JM, Caillou B, et al: Expression of the Na+/I- symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234, 1999
41. Segev DL, Clark DP, Zeiger MA, et al: Beyond the suspicious thyroid fine needle aspirate: A review. Acta Cytol 47:709-722, 2003
42. Bergstrom JD, Westermark B, Heldin NE: Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259:293-299, 2000
43. Jarzab B, Wiench M, Fujarewicz K, et al: Gene expression profile of papillary thyroid cancer: Sources of variability and diagnostic implications. Cancer Res 65:1587-1597, 2005
44. Huang Y, de la Chapelle A, Pellegata NS: Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104:735-744, 2003
45. O'Donovan N, Fischer A, Abdo EM, et al: Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas. J Endocrinol 174:517-524, 2002
46. Finley DJ, Zhu B, Barden CB, et al: Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425-437, 2004
47. Weber F, Shen L, Aldred MA, et al: Genetic classification of benign and malignant thyroid follicular neoplasia based on a 3-gene combination. J Clin Endocrinol Metab 90:2512-2521, 2005
48. Giordano TJ, Kuick R, Thomas DG, et al: Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-6656, 2005
49. Barden CB, Shister KW, Zhu B, et al: Classification of follicular thyroid tumors by molecular signature: Results of gene profiling. Clin Cancer Res 9:1792-1800, 2003
50. Chen KT, Lin JD, Chao TC, et al: Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 11:41-46, 2001
51. Aldred MA, Huang Y, Liyanarachchi S, et al: Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531-3539, 2004
52. Cerutti JM, Delcelo R, Amadei MJ, et al: A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242, 2004
53. Eszlinger M, Krohn K, Paschke R: Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J Clin Endocrinol Metab 86:4834-4842, 2001
54. Zou M, Famulski KS, Parhar RS, et al: Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: Identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 89:6146-6154, 2004
55. Mazzanti C, Zeiger MA, Costouros NG, et al: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903, 2004
56. Takano T, Hasegawa Y, Matsuzuka F, et al: Gene expression profiles in thyroid carcinomas. Br J Cancer 83:1495-1502, 2000
57. Pauws E, Veenboer GJ, Smit JW, et al: Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles. Faseb J 18:560-561, 2004
58. Scarpino S, Cancellario d'Alena F, Di Napoli A, et al: Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352-358, 2004
59. Nardone HC, Ziober AF, LiVolsi VA, et al: C-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer 98:1386-1393, 2003
60. Mineo R, Costantino A, Frasca F, et al: Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: Biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 145:4355-4365, 2004
61. Shi Y, Parhar RS, Zou M, et al: Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma. Br J Cancer 79:1234-1239, 1999
62. Umeki K, Tanaka T, Yamamoto I, et al: Differential expression of dipeptidyl peptidase IV (CD26) and thyroid peroxidase in neoplastic thyroid tissues. Endocr J 43:53-60, 1996